Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Syed Hasan

Psychiatry Brooksville, FL Medical Doctor

NPI 1952325029 CMS profile 134460

7074 Grove Rd, Brooksville, FL 34609

Open in the dashboard

General payments

$833

41 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$20,708 paid to institutions, not to them · program year 2020

Through program year 2025, Syed Hasan of Brooksville, FL is reported in the CMS Open Payments database as having received $833 across 41 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $20,708 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 68th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $86 4
2024 General $39 2
2023 General $26 1
2022 General $201 10
2021 General $152 3
2020 General $181 11
2019 General $149 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Syed Hasan
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Syed Hasan were reported at $86. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Syed Hasan Psychiatry median Middle half National median
2019 $149 $184 $59–$605 $163
2020 $181 $119 $36–$372 $114
2021 $152 $143 $43–$576 $132
2022 $201 $153 $50–$590 $149
2023 $26 $170 $56–$651 $160
2024 $39 $179 $57–$673 $164
2025 $86 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $319 19 payments
  2. Janssen Biotech, Inc. $125 1 payment
  3. Neurocrine Biosciences, Inc. $78 3 payments
  4. Otsuka America Pharmaceutical, Inc. $75 5 payments
  5. E.R. Squibb & Sons, L.L.C. $71 3 payments
  6. Janssen Pharmaceuticals, Inc $70 4 payments
  7. Alkermes, Inc. $47 3 payments
  8. Pfizer Inc. $29 2 payments
  9. Sunovion Pharmaceuticals Inc. $20 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $833 41 payments
Products named General payments · program years 2019–2025
  1. Ozempic $278 16 payments
  2. RYBELSUS $257 15 payments
  3. IMBRUVICA $125 1 payment
  4. INGREZZA $78 3 payments
  5. COBENFY $71 3 payments
  6. ABILIFY MAINTENA $59 4 payments
  7. Tresiba $56 4 payments
  8. INVEGA SUSTENNA $48 3 payments
  9. Victoza $41 3 payments
  10. Xultophy 100/3.6 $41 3 payments
  11. Other $205 13 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

40

Median for Psychiatry: 574

Drug cost

$213

Median for Psychiatry: $27,624

Branded share of claims

0%

Median for Psychiatry: 17%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Escitalopram Oxalate Generic 12 $90
Quetiapine Fumarate Generic 17 $68
Alprazolam Generic 11 $55

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 20,488 Part D prescribers listed as Psychiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$32,826

Medicare's payments for the services billed

Medicare patients

337

Average age 72

Services billed

438

191 women, 146 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 75%
Alzheimer's or dementia 64%
Diabetes 50%
Arthritis 49%
Ischemic heart disease 39%
Chronic kidney disease 34%
COPD 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

2 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SPRAVATO
  • Janssen Pharmaceuticals, Inc $23
$23 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

41 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record